Xconomy | Boston - Business + Technology in the Exponential Economy

Alnylam Buys More RNAi Patents From Nucleonics

Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) said today it has acquired a load of intellectual property that includes more than 100 active patent applications and 16 issued patents worldwide from Langhorne, PA-based Nucleonics. The intellectual property is meant to strengthen Alnylam’s grip on its right to develop drugs using RNA Interference technology, or gene silencing. Terms of the purchase weren’t disclosed, although Alnylam said it still expects to finish the year with more than $500 million in cash and investments, as it previously forecast.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments (1) | Reprints | Share:

Links to This Post

Alnylam Pharmaceuticals (ALNY) « Ask Lazlo
12/14/08 4:56 am

[...] Purchased 116 pieces of IP from Nucleonics (Dec. 8, 2008) Looks like Alnylam is making a move to cluster and consolidate its presence in the RNAi space in [...]